UMIN-CTR Clinical Trial
| Unique ID issued by UMIN | UMIN000003920 |
|---|---|
| Receipt number | R000004712 |
| Scientific Title | Clinical research of glibenclamide, warfarin, metoprolol, lansoprazole and dextromethorphan cocktail-microdose to validate the utility of microdose study on the Cytochrome P450 SNP's |
| Date of disclosure of the study information | 2010/08/01 |
| Last modified on | 2011/01/20 14:50:19 |
* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments
Basic information
Public title
Clinical research of glibenclamide, warfarin, metoprolol, lansoprazole and dextromethorphan cocktail-microdose to validate the utility of microdose study on the Cytochrome P450 SNP's
Acronym
CYP probe cocktail-microdose
Scientific Title
Clinical research of glibenclamide, warfarin, metoprolol, lansoprazole and dextromethorphan cocktail-microdose to validate the utility of microdose study on the Cytochrome P450 SNP's
Scientific Title:Acronym
CYP probe cocktail-microdose
Region
| Japan |
Condition
Condition
healthy male
Classification by specialty
| Not applicable |
Classification by malignancy
Others
Genomic information
YES
Objectives
Narrative objectives1
To evaluate PK profiles of cocktail-dose of glibenclamide, warfarin, metoprolol, lansoprazole and dextromethorphan, and to assess the effect of dosage form, then to identify the relationship between PK profiles and regarded genes.
Basic objectives2
Pharmacokinetics
Basic objectives -Others
Trial characteristics_1
Trial characteristics_2
Developmental phase
Assessment
Primary outcomes
PK profiles of glibenclamide, warfarin, metoprolol, lansoprazole and dextromethorphan
Key secondary outcomes
Base
Study type
Interventional
Study design
Basic design
Single arm
Randomization
Non-randomized
Randomization unit
Blinding
Open -no one is blinded
Control
Uncontrolled
Stratification
Dynamic allocation
Institution consideration
Blocking
Concealment
Intervention
No. of arms
1
Purpose of intervention
Treatment
Type of intervention
| Medicine |
Interventions/Control_1
glibenclamide, warfarin, metoprolol, lansoprazole and dextromethorphan
Interventions/Control_2
Interventions/Control_3
Interventions/Control_4
Interventions/Control_5
Interventions/Control_6
Interventions/Control_7
Interventions/Control_8
Interventions/Control_9
Interventions/Control_10
Eligibility
Age-lower limit
| 20 | years-old | <= |
Age-upper limit
| 45 | years-old | >= |
Gender
Male
Key inclusion criteria
the investigors must ensure that all subjects being considerd meet the following inclusion
criteria: 1) Japanese healthy male who is capable to understand and sign the informed consent. 2) 20-45 years of age 3)BMI 18.5-25.0 4)good health as determined by physical examination, vital signs and laboartory tests.
Key exclusion criteria
the investigors must ensure that all subjects being considerd meet the following exclusion criteria or conditions: 1)history of allergy to any drugs 2)medical attention within 2 months prior to participation 3)donation of 200mL or more of blood within 4 weeks prior to participation, or donation of component blood within 2 weeks prior to participation 4)donation of 400mL or more of blood within 12 weeks prior to participation 5)recent (past 4 months) participation in other clinical trial for investigational new chemical entity 6)history of drug abuse 7)alcohol abuse 8)lactose intolerance
Target sample size
20
Research contact person
Name of lead principal investigator
| 1st name | |
| Middle name | |
| Last name | Shin Irie |
Organization
ETA
Division name
Kyushu Clinical Pharmacology Clinic
Zip code
Address
2-13-16 Jigyo Fukuoka
TEL
Public contact
Name of contact person
| 1st name | |
| Middle name | |
| Last name | Miyuki Kimura |
Organization
ETA
Division name
Kyushu Clinical Pharmacology Clinic
Zip code
Address
TEL
092-733-1001
Homepage URL
Sponsor or person
Institute
APDD
Institute
Department
Personal name
Funding Source
Organization
APDD
Organization
Division
Category of Funding Organization
Nationality of Funding Organization
Other related organizations
Co-sponsor
Name of secondary funder(s)
IRB Contact (For public release)
Organization
Address
Tel
Secondary IDs
Secondary IDs
NO
Study ID_1
Org. issuing International ID_1
Study ID_2
Org. issuing International ID_2
IND to MHLW
Institutions
Institutions
Other administrative information
Date of disclosure of the study information
| 2010 | Year | 08 | Month | 01 | Day |
Related information
URL releasing protocol
Publication of results
Unpublished
Result
URL related to results and publications
Number of participants that the trial has enrolled
Results
Results date posted
Results Delayed
Results Delay Reason
Date of the first journal publication of results
Baseline Characteristics
Participant flow
Adverse events
Outcome measures
Plan to share IPD
IPD sharing Plan description
Progress
Recruitment status
Completed
Date of protocol fixation
| 2010 | Year | 06 | Month | 21 | Day |
Date of IRB
Anticipated trial start date
| 2010 | Year | 07 | Month | 01 | Day |
Last follow-up date
| 2011 | Year | 03 | Month | 01 | Day |
Date of closure to data entry
Date trial data considered complete
Date analysis concluded
Other
Other related information
Management information
Registered date
| 2010 | Year | 07 | Month | 16 | Day |
Last modified on
| 2011 | Year | 01 | Month | 20 | Day |
Link to view the page
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000004712
